EHA 2019 | Current CML treatments: which TKI to choose?

Gianantonio Rosti

Gianantonio Rosti, MD, Institute of Hematology ‘Seragnoli’, Bologna, Italy, discusses the current landscape of chronic myeloid leukemia (CML) treatment, as well as the importance of consistent long-term monitoring. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video